Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208
Received 16 December 2005/ Returned for modification 18 January 2006/ Accepted 11 March 2006
| ABSTRACT |
|---|
|
|
|---|
| TEXT |
|---|
|
|
|---|
An attenuated live vaccine strain (LVS) derived from a type B strain of F. tularensis has served as an invaluable tool in the study of tularemia pathogenesis (7, 8, 30). This strain, while not infectious for humans, is virulent in laboratory mice and causes a fulminant and lethal infection with features reminiscent of human tularemia (13, 29, 30). Despite these similarities, immunity to F. tularensis is not completely understood, particularly the early innate responses that contribute to inflammation, pathology, and the subsequent generation of adaptive immunity.
Toll-like receptors (TLRs) represent an ancient family of proteins that have been implicated in host antimicrobial defenses and in coordinating both innate and adaptive immune responses to pathogens (22). TLRs are expressed on a number of immune effector cells including monocytes/macrophages, neutrophils, dendritic cells, and both epithelial and endothelial cells. TLR2 recognizes a variety of pathogen-associated molecular patterns including bacterial lipoproteins (1, 3, 11, 14), peptidoglycan (5, 12), lipoarabinomannan (28), lipoteichoic acid (5), porins (17), and ß-glucan (the cell-stimulatory component of zymosan) (18, 20). It has been demonstrated that TLR2 forms heterodimers in association with TLR1 or TLR6 (20), which could in part explain the ability of TLR2 to recognize such diverse pathogen-associated molecular patterns. To date, the role of this important pattern recognition receptor in innate immunity to F. tularensis has not been investigated.
To explore the role of TLR2 in host resistance to F. tularensis infection, we employed TLR2/ mice backcrossed onto a C57BL/6 background for 10 generations and used their congenic C57BL/6 wild-type (TLR2+/+) counterparts as controls. F. tularensis LVS (ATCC 29684; American Type Culture Collection, Rockville, MD) was kindly provided by Karen Elkins (U.S. Food and Drug Administration, Bethesda, MD), and aliquots of mid-log-phase growth cultures were stored in liquid nitrogen. For each experiment, the viability of frozen aliquots of bacteria and the inocula dosage after serial dilution in phosphate-buffered saline (PBS) were confirmed by colony counting. Mice were inoculated intranasally with 104, 103, or 102 CFU of F. tularensis LVS in a volume of 20 µl of PBS (10 µl per nare) or with an equal volume of PBS alone. The relative susceptibility of mice to infection was based upon cumulative survival proportions and median time to death (MTD) of the entire group of mice. A log rank test was used to determine the level of significance for the Kaplan-Meir survival analyses. Differences between control and experimental groups were considered significant at a P value of <0.05.
With an inoculum of 104 CFU of F. tularensis, TLR2+/+ mice had an MTD of 10 days, while TLR2/ mice died more rapidly, with an MTD of only 6.5 days (Fig. 1 and Table 1). Although reducing the inoculum size lengthened the MTD, TLR2 deficiency hastened death in all cases. These results suggest that signaling through TLR2 enhances host resistance to F. tularensis infection. To determine whether the increased mortality observed in TLR2/ mice reflects an impaired ability to control bacterial replication, we quantified the bacterial burden in various tissues. Mice were infected with 103 CFU of F. tularensis, and lungs, liver, and spleen were removed at various times postinfection. Portions of lung (20 mg), liver (30 mg), and spleen (5 mg) were homogenized in 0.5 ml of sterile PBS containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), and 10-fold serial dilutions of clarified supernatant were spotted onto Mueller Hinton II chocolate agar plates to enumerate the bacterial colonies. At days 5 and 7 postinfection, the number of bacteria was consistently higher in the tissues of TLR2/ mice than in TLR2+/+ mice. Bacterial burden in the lungs of TLR2/ mice was nearly 3 logs higher than in wild-type animals. Under these experimental conditions, the earliest point at which bacteria were detected in the liver and spleen of either genotype was 2 days postinfection (unpublished data). Compared with TLR2+/+ mice, bacterial burden in the TLR2/ mice was significantly higher by day 5 for the liver and by day 3 for the spleen (Fig. 2). Comparisons between the groups were made using one-way analysis of variance (ANOVA), followed by Bonferroni's correction or nonparametric Mann-Whitney test. These findings demonstrate that the increased susceptibility to infection observed in TLR2/ mice is associated with either an impaired ability to control bacterial growth and/or eliminate organisms from infected tissues.
|
|
|
|
|
) and interleukin-6 (IL-6), two proinflammatory cytokines required for resistance to F. tularensis (9, 26), were significantly lower in the lungs of infected TLR2/ mice than in their wild-type counterparts. However, by day 7 postinfection levels of interferon gamma (IFN-
) and monocyte chemoattractant protein 1 (MCP-1) were significantly elevated in the lungs of TLR2/ mice (Fig. 4). With the exception of IL-6, there was a progressive increase in immunomodulator levels over time. In contrast, it was consistently observed that IL-6 production began after 3 days of infection, peaked by 5 days, and returned to baseline levels by day 7. Although levels of active IL-12 (i.e., IL-12p70) were below detectable limits, an elevation in the level of the IL-12p40 subunit was observed (unpublished data). For a brief period early in the disease process, IL-12p40 levels were higher in TLR2+/+ than in TLR2/ mice; however, by day 5 postinfection, the reverse was observed, with higher levels seen in mice deficient for TLR2. In contrast, IL-10 levels never rose above detectable limits for the duration of the experiment (unpublished data).
|
were released by F. tularensis-stimulated TLR2/ BMDM (Fig. 5C).
|
and IL-6 production was significantly lower in TLR2/ mice than in their wild-type counterparts. Further, TLR2/ mice infected with F. tularensis harbored greater numbers of organisms and developed more severe and extensive pathology. Our finding is reminiscent of the failure of mice to clear Legionella pneumophila and to exhibit persistent pneumonitis following antibody-mediated depletion of TNF-
(24). TNF-
is known to enhance the L. pneumophila-killing activity of rat alveolar macrophages via its ability to potentiate the activating effects of IFN-
through induction of nitric oxide synthesis (25). IFN-
, nitric oxide, and IL-12 are known to be critical elements of innate immunity to F. tularensis (4, 6, 15). Importantly, the full microbicidal action of IFN-
is not realized in the absence of the synergistic influence of TNF-
. Thus, despite the higher IFN-
levels observed in TLR2/ mice, diminished production of TNF-
results in less effective control of F. tularensis growth. This interpretation is further supported by results presented in Fig. 5A, wherein TLR2/ macrophages harbor significantly greater numbers of bacteria than their wild-type counterparts. Despite the fact that elevated levels of IL-6 are associated with many pathophysiological processes including the development of chronic inflammation (10, 27), this multifunctional cytokine also plays an important "positive" role as a differentiation and growth factor for B and T cells (27) and as a modulator of the suppressor activity of CD4+ CD25+ T cells (21). In the Chlamydia trachomatis model, IL-6/ mice present with increased mortality, higher bacterial burdens, and altered histological findings (32). The phenotypic similarity between C. trachomatis-infected IL-6/ mice and F. tularensis-infected TLR2/ mice suggests that lower IL-6 levels in the latter may contribute to, rather than result from, greater pathology. TLR-mediated release of IL-6 is known to "unblock" the suppressive effect that CD4+ CD25+ T cells have on pathogen-specific effector T cells (21). In our model where IL-6 levels are lower in TLR2/ mice, the actions of F. tularensis-specific effector T cells may remain partially suppressed by CD4+ CD25+ T cells, thus resulting in less effective adaptive immune responses. Suboptimal adaptive immunity may, in part, contribute to the larger numbers of TLR2/ mice that succumb to infection between days 7 and 14.
Although paradoxical given the typical association of TNF-
and IL-6 with tissue damage and establishment of chronic inflammation, respectively, diminished levels of these cytokines in TLR2/ mice may undermine clearance mechanisms, thus allowing greater replication of F. tularensis and exacerbation of disease via production of other proinflammatory molecules. IFN-
and MCP-1 are modulators of inflammation that variably contribute both to bacterial clearance and tissue damage. Recently, IL-12-induced IFN-
was shown to be necessary for the protection of mice against lethal respiratory tularemia (4). Nevertheless, production of IFN-
appears insufficient to prevent death, as evidenced by greater levels of this potent stimulator of macrophage antimicrobial action in highly susceptible TLR2/ mice. Despite higher IFN-
levels, bacterial burdens in the lungs, liver, and spleen of TLR2/ mice exceeded by several logs the number of francisellae in wild-type mice. Consistent with this observation is the finding that although IFN-
is required for control of tularemia, its excessive production does not result in more effective killing of F. tularensis (15). One potential explanation for this paradoxical observation is that MCP-1 levels are significantly elevated in TLR2/ mice as well. A potent stimulus for macrophage recruitment to sites of bacterial insult, MCP-1 may facilitate the accumulation of macrophages in the lungs of TLR2/ mice, thus providing a larger pool of cells in which F. tularensis can replicate.
The more severe course of disease in TLR2/ mice raised an intriguing question. Does the TLR2 deficiency phenotype reflect a primary TLR2-mediated response or secondary responses resulting from bacterial replication in the lungs? To answer this question UV-killed francisellae were instilled in the lungs of mice, and it was observed that this inoculum failed to elicit any pulmonary histopathological changes or stimulate the production of cytokines at a point in time when fulminant inflammatory responses were elicited by viable organisms in both TLR2+/+ and TLR2/ mice (unpublished data). A lymphoproliferative response, however, was observed in spleens of mice receiving UV-killed F. tularensis. These findings lead us to propose that both the primary (a direct result of bacterial recognition) and secondary (inflammation) responses to F. tularensis are mediated by and are a consequence of TLR2 signaling events.
Finally, Mariathasan and coworkers recently reported that activation of the ASC/caspase-1 axis is essential for innate immunity against F. tularensis (16). F. tularensis infection of mice deficient for ASC or caspase-1 was associated with markedly increased mortality, bacterial burdens, and pathology compared with wild-type mice, a phenotype shared by TLR2/ mice. This intriguing similarity is perhaps not surprising given that binding of bacterial lipoproteins to TLR2 on macrophages induces caspase-1 and triggers subsequent apoptosis (2). Although no component of F. tularensis has yet been definitively identified as a TLR2 ligand, possible candidates include lipoproteins such as Tul4 (23) and ß-glucan (31). Whether either or both of these putative ligands act directly through TLR2 to engage the ASC/caspase-1 axis and trigger antibacterial defense mechanisms such as apoptosis requires further investigation. Regardless, our results demonstrate a central role for TLR2 in tularemia pathogenesis and suggest that failure to engage this signaling pathway drastically impairs host immunity to F. tularensis.
| ACKNOWLEDGMENTS |
|---|
We are indebted to Paul Feustal for discussions on biostatistics, James Drake and Karsten Hazlett for critical review of the manuscript, and the Center for Immunology and Microbial Disease Immunology Core Facility.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285:736-739. |
| 2. | Aliprantis, A. O., R. B. Yang, D. S. Weiss, P. Godowski, and A. Zychlinsky. 2000. The apoptotic signaling pathway activated by toll-like receptor-2. EMBO J. 19:3325-3336.[CrossRef][Medline] |
| 3. | Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. B. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736. |
| 4. | Duckett, N. S., S. Olmos, D. M. Durrant, and D. W. Metzger. 2005. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun. 73:2306-2311. |
| 5. | Dziarski, R., Q. L. Wang, K. Miyake, C. J. Kirschning, and D. Gupta. 2001. MD-2 enables toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to gram-positive and gram-negative bacteria and their cell wall components. J. Immunol. 166:1938-1944. |
| 6. | Elkins, K. L., S. C. Cowley, and C. M. Bosio. 2003. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 5:135-142.[CrossRef][Medline] |
| 7. | Elkins, K. L., T. R. Rhinehart-Jones, S. J. Culkin, D. Yee, and R. K. Winegar. 1996. Minimal requirements for murine resistance to infection with Francisella tularesis LVS. Infect. Immun. 64:3288-3293.[Abstract] |
| 8. | Fortier, A. H., M. V. Slayter, R. Ziemba, M. S. Meltzer, and C. A. Nacy. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59:2922-2928. |
| 9. | Golovliov, I., G. Sandstrom, M. Ericsson, A. Sjostedt, and A. Tarnvik. 1995. Cytokine expression in the liver during the early phase of murine tularemia. Infect. Immun. 63:534-538.[Abstract] |
| 10. | Hirano, T., S. Akira, T. Taga, and T. Kishimoto. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today 11:443-449.[CrossRef][Medline] |
| 11. | Hirschfeld, M., C. J. Kirschning, R. Schwandner, H. Wesche, J. H. Weis, R. M. Wooten, and J. J. Weis. 1999. Inflammatory signaling by Borrelia burgdorferi lipoporteins is mediated by Toll-like receptor 2. J. Immunol. 163:2382-2386. |
| 12. | Iwaki, D., H. Mitsuzawa, S. Murakami, H. Sano, M. Konishi, T. Akino, and Y. Kuroki. 2002. The extracellular Toll-like receptor 2 domain directly binds peptidoglycan derived from Staphylococcus aureus. J. Biol. Chem. 277:24315-24320. |
| 13. | Lamps, L. W., J. M. Havens, A. Sjostedt, D. L. Page, and M. A. Scott. 2004. Histologic and molecular diagnosis of tularemia: a potential bioterrorism agent endemic to North America. Mod. Pathol. 17:489-495.[CrossRef][Medline] |
| 14. | Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274:33419-33425. |
| 15. | Lindgren, H., L. Stenman, A. Tarnvik, and A. Sjostedt. 2005. The contribution of reactive nitrogen and oxygen species to the killing of Francisella tularensis LVS by murine macrophages. Microbes Infect. 7:467-475.[CrossRef][Medline] |
| 16. | Mariathasan, S., D. S. Weiss, V. M. Dixit, and D. M. Monack. 2005. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J. Exp. Med. 202:1043-1049. |
| 17. | Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 168:1533-1537. |
| 18. | McCurdy, J. D., T. J. Olynych, L. H. Maher, and J. S. Marshall. 2003. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170:1625-1629. |
| 19. | Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2:967-978.[CrossRef][Medline] |
| 20. | Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 97:13766-13771. |
| 21. | Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T-cell-mediated suppression by dendritic cells. Science 299:1033-1036. |
| 22. | Pasare, C., and R. Medzhitov. 2004. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 6:1382-1387.[CrossRef][Medline] |
| 23. | Sjostedt, A., G. Sandstrom, and A. Tarnvik. 1992. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect. Immun. 60:2855-2862. |
| 24. | Skerrett, S. J., G. J. Bagby, R. A. Schmidt, and S. Nelson. 1997. Antibody-mediated depletion of tumor necrosis factor-alpha impairs pulmonary host defenses to Legionella pneumophila. J. Infect. Dis. 176:1019-1028.[Medline] |
| 25. | Skerrett, S. J., and T. R. Martin. 1996. Roles for tumor necrosis factor alpha and nitric oxide in resistance of rat alveolar macrophages to Legionella pneumophila. Infect. Immun. 64:3236-3243.[Abstract] |
| 26. | Stenmark, S., D. Sunnemark, A. Bucht, and A. Sjostedt. 1999. Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect. Immun. 67:1789-1797. |
| 27. | Taga, T., and T. Kishimoto. 1997. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:797-819.[CrossRef][Medline] |
| 28. | Tapping, R. I., and P. S. Tobias. 2003. Mycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signaling. J. Endotoxin Res. 9:264-268.[Medline] |
| 29. | Tarnvik, A., M. Ericsson, I. Golovliov, G. Sandstrom, and A. Sjostedt. 1996. Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism. FEMS Immunol. Med. Microbiol. 13:221-225.[CrossRef][Medline] |
| 30. | Tarnvik, A., M. Eriksson, G. Sandstrom, and A. Sjostedt. 1992. Francisella tularensisa model for studies of the immune response to intracellular bacteria in man. Immunology 76:349-354.[Medline] |
| 31. | Vinogradov, E., M. B. Perry, and J. W. Conlan. 2002. Structural analysis of Francisella tularensis lipopolysaccharide. Eur. J. Biochem. 269:6112-6118.[Medline] |
| 32. | Williams, D. M., B. G. Grubbs, T. Darville, K. Kelly, and R. G. Rank. 1998. A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection. Infect. Immun. 66:4564-4567. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|